P

Phio Pharmaceuticals Corp
D

PHIO

1.66000
USD
-0.05
(-2.92%)
مغلق
حجم التداول
1,134
الربح لكل سهم
4
العائد الربحي
-
P/E
-0
حجم السوق
7,929,568
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ABUS
    -0.01500
    (-0.44%)
    3.42500 USD
    A
    ALT
    -0.19000
    (-2.87%)
    6.42000 USD
    A
    ARCT
    0.846
    (5.00%)
    17.770 USD
    BNTX
    BNTX
    2.240
    (1.90%)
    120.100 USD
    I
    INO
    0.02000
    (0.91%)
    2.23000 USD
    MRNA
    MRNA
    1.785
    (5.29%)
    35.535 USD
    N
    NVAX
    0.05500
    (0.69%)
    7.98000 USD
    V
    VIR
    -0.22000
    (-2.24%)
    9.58000 USD
    V
    VXRT
    0.00670
    (0.95%)
    0.70980 USD
    المزيد
الأخبار
المقالات

العنوان: Phio Pharmaceuticals Corp

القطاع: Healthcare
الصناعة: Biotechnology
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.